DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 5, 2013, Pages 829-834

  Keyes, Mira ^a   Macaulay, Calum ^c   Hayes, Malcolm ^b   Korbelik, Jagoda ^c   Morris, W James ^a   Palcic, Branko ^c  

^a Radiation   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE FREE SURVIVAL; LOCALIZED PROSTATE CANCER; METHODS AND MATERIALS; MULTIVARIABLE ANALYSIS; PROSTATE BRACHYTHERAPY; PROSTATE CANCER CELLS; PROSTATE SPECIFIC ANTIGEN; ULTRASOUND-GUIDED;

ANTIGENS; BIOPSY; CYTOLOGY; DISEASES; DOSIMETRY; ONCOLOGY; PARAFFINS; PATIENT MONITORING; RADIOTHERAPY; TUMORS; UROLOGY;

DNA;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DISEASE FREE SURVIVAL; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; PLOIDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TREATMENT FAILURE;

AGED; ANALYSIS OF VARIANCE; ANEUPLOIDY; BRACHYTHERAPY; CASE-CONTROL STUDIES; DIPLOIDY; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT FAILURE;

EID: 84880039692     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.04.011     Document Type: Article

References (24)

1. P.D. Grimm, I. Billiet, and D.G. Bostwick Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group BJU Int 109 Suppl. 1 2012 22 29
2. W.J. Morris, M. Keyes, and I. Spadinger Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer Cancer 119 2013 1537 1546
3. M. Keyes, I. Spadinger, and M. Liu Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: A long-term study in 1006 patients Brachytherapy 11 2012 199 208
4. M. Keyes, S. Miller, and V. Moravan Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients Int J Radiat Oncol Biol Phys 73 2009 1023 1032
5. M.R. Cooperberg, J.E. Cowan, and J.F. Hilton Outcomes of active surveillance for men with intermediate-risk prostate cancer J Clin Oncol 29 2011 228 234
6. L. Klotz, L. Zhang, and A. Lam Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
7. D.W. Lin, L.M. FitzGerald, and R. Fu Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality Cancer Epidemiol Biomarkers Prev 20 2011 1928 1936
8. A. Böcking, F. Giroud, and A. Reith Consensus report of the ESACP task force on standardization of diagnostic DNA image cytometry Anal Cell Pathol 8 1995 67 74
9. J. Kaern, J. Wetteland, and C.G. Trope Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer Cytometry 13 1992 314 321
10. J.W. Bacus, C.W. Boone, and J.V. Bacus Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials Cancer Epidemiol Biomarkers Prev 8 1999 1087 1094 (Pubitemid 30004906)
11. M.J. Carmichael, R.W. Veltri, and A.W. Partin Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease J Urol 153 3 Pt. 2 1995 1015 1019
12. M.E. Pretorius, H. Waehre, and V.M. Abeler Large scale genomic instability as an additive prognostic marker in early prostate cancer Cell Oncol 31 2009 251 259
13. A. Pollack, D.J. Grignon, and K.H. Heydon Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: An analysis of RTOG 8610 J Clin Oncol 21 2003 1238 1248 (Pubitemid 46606399)
14. S. Isharwal, M.C. Miller, and J.I. Epstein DNA ploidy as surrogate for biopsy Gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction Urology 73 2009 1092 1097
15. S. Isharwal, M.C. Miller, and J.I. Epstein Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy Int J Cancer 123 2008 2636 2643
16. V.T. Shankey, O.P. Kallioniemi, and J.M. Koslowski Consensus review of the clinical utility of DNA content cytometry in prostate cancer Cytometry 14 1993 497 500 (Pubitemid 23191959)
17. G. Li, M. Guillaud, and J. LeRiche Automated sputum cytometry for detection of intraepithelial neoplasias in the lung Anal Cell Pathol (Amst) 35 2012 187 201
18. H. Tong, R. Shen, and Z. Wang DNA ploidy cytometry testing for cervical cancer screening in China (DNACIC Trial): A prospective randomized, controlled trial Clin Cancer Res 15 2009 6438 6445
19. A. Bantis, E. Patsouris, and M. Gonidi Telomerase RNA expression and DNA ploidy as prognostic markers of prostate carcinomas Tumori 95 2009 744 752
20. J.F. Ward, J.M. Slezak, and M.L. Blute Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome BJU Int 95 2005 751 756 (Pubitemid 40547200)
21. G. Ahlgren, K. Lindholm, and U. Falkmer A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate Urology 50 1997 379 384 (Pubitemid 27428115)
22. R. Orozco, G. O'Dowd, and B. Kunnel Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States Urology 51 1998 186 195 (Pubitemid 28093166)
23. L. Haggarth, G. Auer, and C. Busch The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer Scand J Urol Nephrol 39 2005 387 392 (Pubitemid 41666022)
24. B. Tribukai Nuclear deoxyribonucleic acid determination in patients with prostate carcinoma: Clinical reseach and application Eur Urol 23 Suppl. 2 1993 64 76